# Single Dose Escalation Study of GSK2838232 in Healthy Subjects

> **NCT01802918** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 17 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** GSK2838232
- **DRUG:** Placebo
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT01802918
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-18
- **Primary completion:** 2013-11-21
- **Final completion:** 2013-11-21
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2017-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01802918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01802918, "Single Dose Escalation Study of GSK2838232 in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01802918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*